|
|
Post by peppy on Jul 16, 2016 9:28:01 GMT -5
|
|
|
|
Post by patten1962 on Jul 16, 2016 9:42:30 GMT -5
Ever see a snowball roll down a mountain? Salesforce are the people rolling it! |
|
Deleted
Deleted Member
Posts: 0
|
Rx Targets
Jul 16, 2016 10:06:15 GMT -5
via mobile
Post by Deleted on Jul 16, 2016 10:06:15 GMT -5
I am expecting a target of getting of 25k to 30 k patients on Afrezza by the sales team by the end of year. Is that possible?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 16, 2016 10:09:26 GMT -5
I am expecting a target of getting of 25k to 30 k patients on Afrezza by the sales team by the end of year. Is that possible? It depends on which poster you are impersonating lol |
|
Deleted
Deleted Member
Posts: 0
|
Rx Targets
Jul 16, 2016 10:13:08 GMT -5
via mobile
Post by Deleted on Jul 16, 2016 10:13:08 GMT -5
I am expecting a target of getting of 25k to 30 k patients on Afrezza by the sales team by the end of year. Is that possible? It depends on which poster you are impersonating lol I didn't get you |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 16, 2016 10:16:17 GMT -5
It depends on which poster you are impersonating lol I didn't get you I thought you were being sarcastic...lol You really expect 30,000 scripts by the end of the year? I thought you were trying to impersonate some of our bullish investors/members |
|
|
|
Post by prosper on Jul 16, 2016 10:17:01 GMT -5
Unfortunately we are starting from less than zero in many ways. Because of the botched intro by SNY we had people started on A and then lost them. Those were the relatively easy pickings of both doctors and patients. We now have to overcome the negatives felt by/of those in both categories. The reps have to have specific reasons for failures.
I hope Mike and gang have thorough explanations to present to doctors who through both experience and word of mouth have negative opinions of A.
|
|
|
|
Post by peppy on Jul 16, 2016 10:30:03 GMT -5
Ever see a snowball roll down a mountain? Salesforce are the people rolling it! It seems to me it is up to the few endos and practitioners in the know to prescribe Afrezza. Non of the above can be said, because it is not found on the label. Afrezza works so differently than the status quo fast acting analogs. screencast.com/t/Ui2v2r9y4nS So far Afrezza is an elite, niche drug because only the lucky, the well informed and the diabetics with the most monetary resources and support have gotten the option of trying it. Frankly, the endo's looked scared to me. What doesn't make sense to me in that regard, is every drug effects an organ system. Whether it is the liver and kidneys, vasculature.... Endo's prescribe many drugs for all the endocrine system.
Endo's are busy people, prescribing over the whole system. change comes slowly. It seems to me our best bet is demand. Eric has video after video on you tube. I am just talking. www.mannkindcorp.com/Collateral/Documents/English-US/Baughman%20poster%20100-LB%20FINAL%20X2.pdf
|
|
|
|
Post by daduke38 on Jul 16, 2016 10:52:53 GMT -5
Been reading a lot on here about what can be said and what can't. If sales reps can only say what is on the label, how do drugs get used for off label needs?
For example, my daughter had Post-concussion Syndrome a few years back. It was a scary period in our lives. After taking her to a top neurologist at Duke, I was kind of surprised he put her on Cymbalta. And it wasn't due to any depression. And guess what, it worked.
So, how does this happen? I am sure it was accidentally found to work and word spread. But I bet it isn't on the label for Concussion treatment.
|
|
|
|
Post by agedhippie on Jul 16, 2016 10:56:02 GMT -5
The problem with the posters from the ADA is that they say Afrezza has fast onset and fast clearance but it makes no difference to the outcome according to the label. In other words it has nice features but no benefit. As an analogy: on a long flight you could go first class or coach - both get you there but one is a far better experience. I think the doctors may be prepared to go with the better experience with time but can we get the insurers to pay for the patients to have the nicer drug?
|
|
|
|
Post by daduke38 on Jul 16, 2016 10:58:55 GMT -5
And you know every competitor out there is gonna put that in the Doctor's head. Just being honest, but would I start someone on a new regime of treatment, no matter how good, if it may be unavailable in a year? I really believe that is the biggest challenge. And though I hate to think that way, you both bring up a very valid concern. I get for sure what you are saying! But Dr.Combs after hearing the best and the worst is willing to give it a try:-) And I sincerely hope he will be the rule and not the exception. I want this to work so badly on so many different levels and reasons, but I guess I have reached a point of tempered expectations. |
|
|
|
Post by cm5 on Jul 16, 2016 11:02:52 GMT -5
Re: peppy's wish expressed earlier for extra Afrezza for that bowl of popcorn--- How about a sample pack labeled "The Snack Pack" !  Low cost, memorable, needed, inexpensive---- |
|
|
|
Post by sportsrancho on Jul 16, 2016 11:11:31 GMT -5
Been reading a lot on here about what can be said and what can't. If sales reps can only say what is on the label, how do drugs get used for off label needs? For example, my daughter had Post-concussion Syndrome a few years back. It was a scary period in our lives. After taking her to a top neurologist at Duke, I was kind of surprised he put her on Cymbalta. And it wasn't due to any depression. And guess what, it worked. So, how does this happen? I am sure it was accidentally found to work and word spread. But I bet it isn't on the label for Concussion treatment. Good post! And I might add that if Dr. Combs is going to listen to me telling him the right way to dose Afrezza he will be very open to what ever the reps tell him as long as they back it up with examples and facts. He wants real world results. |
|
|
|
Rx Targets
Jul 16, 2016 11:37:23 GMT -5
via mobile
cm5 likes this
Post by sportsrancho on Jul 16, 2016 11:37:23 GMT -5
Ever see a snowball roll down a mountain? Salesforce are the people rolling it! It seems to me it is up to the few endos and practitioners in the know to prescribe Afrezza. Non of the above can be said, because it is not found on the label. Afrezza works so differently than the status quo fast acting analogs. screencast.com/t/Ui2v2r9y4nS So far Afrezza is an elite, niche drug because only the lucky, the well informed and the diabetics with the most monetary resources and support have gotten the option of trying it. Frankly, the endo's looked scared to me. What doesn't make sense to me in that regard, is every drug effects an organ system. Whether it is the liver and kidneys, vasculature.... Endo's prescribe many drugs for all the endocrine system.
Endo's are busy people, prescribing over the whole system. change comes slowly. It seems to me our best bet is demand. Eric has video after video on you tube. I am just talking. www.mannkindcorp.com/Collateral/Documents/English-US/Baughman%20poster%20100-LB%20FINAL%20X2.pdf
Endo's are busy people, prescribing over the whole system. change comes slowly.[/p] It seems to me our best bet is demand.
Patient demand, patient driven, IMO
Also what the reps CAN and CAN NOT say because of the label is different than the reality of what they will say:-)) |
|
|
|
Post by mnkdnut on Jul 16, 2016 13:48:09 GMT -5
Agree that reps will have more or less frank discussions with their endo customers depending on the strength of their relationships. It is MNKD's new advertising agency that is really constrained by the label. They cannot drift over the line, as the FDA will see any borderline advertising. Seems to me that the new outsilin caricature they developed - representing fast response and fast clearance - depends on getting the label changed to support that speed message. Mike C has clearly stated that the PK/PD profile is the differentiating point they are going to push, yet the current label does not support it. I'm very curious to see how clever the agency can be in communicating the speed advantages with no/minimal label support. We all saw how toothless the Sanofi agency's efforts were, but then again, Sanofi was asleep at the wheel at best, saboteurs at worst. In any case, advertising will only help when enough docs are willing to prescribe, and that depends now solely on the new rep's efforts. All the eggs are in that basket, as it sounds like there's no international distributorships or OUS approvals imminent.
|
|
